021-51111890
购物车（）
sales@molnova.cn
UVI 3003
CAS No. 847239-17-2
UVI 3003 ( —— )
产品货号. M24839 CAS No. 847239-17-2
UVI 3003 is a highly selective antagonist of the retinoid X receptor. UVI 3003 inhibits Xenopus and human RXRα in Cos7 cells (IC50s: 0.22 and 0.24 μM, respectively).
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 2MG | ￥356 | 有现货 |
|
| 5MG | ￥551 | 有现货 |
|
| 10MG | ￥988 | 有现货 |
|
| 25MG | ￥2066 | 有现货 |
|
| 50MG | ￥3467 | 有现货 |
|
| 100MG | ￥5176 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称UVI 3003
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述UVI 3003 is a highly selective antagonist of the retinoid X receptor. UVI 3003 inhibits Xenopus and human RXRα in Cos7 cells (IC50s: 0.22 and 0.24 μM, respectively).
-
产品描述UVI 3003 is a highly selective antagonist of the retinoid X receptor. UVI 3003 inhibits Xenopus and human RXRα in Cos7 cells (IC50s: 0.22 and 0.24 μM, respectively).
-
同义词——
-
通路Autophagy
-
靶点Autophagy
-
受体Autophagy;RXRα
-
研究领域——
-
适应症——
化学信息
-
CAS Number847239-17-2
-
分子量436.6
-
分子式C28H36O4
-
纯度>98% (HPLC)
-
溶解度DMSO:100 mg/mL (229.05 mM; Need ultrasonic)
-
SMILESCCCCCOC1=C(C2=CC(/C=C/C(O)=O)=CC=C2O)C=C3C(C(C)(CCC3(C)C)C)=C1
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Zhu J, et al. The unexpected teratogenicity of RXR antagonist UVI3003 via activation of PPARγ in Xenopus tropicalis. Toxicol Appl Pharmacol. 2017 Jan 1;314:91-97.
产品手册
关联产品
-
EACC
EACC selectively inhibits the translocation of autophagosome-specific SNARE Stx17 thereby blocking autophagosome-lysosome fusion.?
-
Cysteamine hydrochlo...
An agent for the treatment of nephropathic cystinosis and an antioxidant; increases intracellular glutathione levels in cystinotic cells, also increases the rates of apoptosis in cystinotic cells.
-
Hemin
Hemin, a physiological erythroid maturation stimulator, is able to induce the expression of critical autophagic genes (Map1a1b (LC3), Beclin-1 gen, Atg5) in an erythroleukemia cell type.
